... Chapter 35 Nanoemulsion Formulations for Tumor- TargetedDelivery 723 Sandip B Tiwari and Mansoor M Amiji Chapter 36 Solid Lipid Nanoparticlesfor Antitumor DrugDelivery ... infections; localized delivery of cytotoxic and anti-angiogenic drugs for solid tumors in novel biodegradable polymeric nanoparticles; intracellular delivery systems for drugs and genes using ... carriers for defined release of anti -tumor agents, as well as very useful fortargeteddelivery of such molecules as contrast agents fortumor imaging Dendritic nanocarriers have been evaluated for...
... with my problems and for being such a wonderful friend Thank you to Dr Robertson for all your inputs for my project and for the well stocked candy jar To all my friends, for support, encouragement ... Luo and Ying He for their friendship I could not have asked for a better group of colleagues to work with To Dr Melissa L Fishel, thank you for getting me started in the lab, for your patience ... AP sites formed These compounds are known to target other molecules and are therefore, not specific for Ape1 which may not make them the best choice of compounds to inhibit Ape1 29 Need for Specific...
... to inhibit both presystemic drug metabolism and P-glycoprotein-mediated drug efflux [18] Several polymers have been proposed as nanocarriers fordrugdelivery systems For example, poly(d,l-lactic ... approved by the US Food and Drug Administration and are the most widely used commercial polymers fordrugdelivery [19, 20] Presently, the only available Doc formulations for clinical use consists ... nanosized polymericnanoparticles represent promising drug- delivery systems which have some advantages such as biodegradability, good biocompatibility, non-toxicity, higher stability, and controlled drug...
... of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis Cytogenet Cell Genet 1999, 84:211-6 Heaney AP, Nelson V, Fernando M, Horwitz G: Transforming events in thyroid tumorigenesis ... prognostic marker for lymph node invasion and tumor recurrence Breast 2004, 13:80-81 Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene from ovarian tumors and ... (pituitary tumor transforming gene) in esophageal cancer Jpn J Clin Oncol 2002, 32:233-237 Honda S, Hayashi M, Kobayashi Y, Ishikawa Y, Nakagawa K, Tsuchiya E: A role for the pituitary tumor- transforming...
... Pure co -polymeric nanoparticles in aqueous medium Co-polymer in H2O+ Drug in solvent Drug loaded in copolymeric nanoparticles Lyophilization Drug loaded dry powder of co -polymeric nanoparticles Figure ... application in drugdelivery J Control Release 2005, 109:169-188 Torchilin VP: Targetedpolymeric micelles fordelivery of poorly soluble drugs Cell Mol Life Sci 2004, 61:2549-2559 Kwon GS: Polymeric ... nanoparticles Figure Synthesis strategy for NIPAAM/VP/PEG-A co -polymeric nanoparticles Synthesis strategy for NIPAAM/VP/PEG-A co -polymeric nanoparticles Please refer to text for additional details NIPAAM...
... (H2cit)4 Therefore, we suggest that Magh-Rh2(H2cit)4 and Lip-Magh-Rh2(H2cit)4 should be considered a suitable and effective platform fordrugdelivery systems that operate more specifically in tumor ... target-specific drugdelivery systems, representing a strategy for enhancement of the therapeutic action of Rh2 (H2cit)4 without affecting normal cells Some anticancer drugs associated with magnetic nanoparticles ... maghemite nanoparticles coated with citrate or rhodium (II) citrate was appropriate for its application as a drugdelivery system Coating with the citrate molecule was able to stabilize our magnetic nanoparticles...
... P(MDS-co-CES )nanoparticles In vivo anti -tumor efficacy studies of P(MDS-co-CES) nanoparticles Distribution of nanocomplexes within tumors INVESTIGATION OF CATIONIC POLYMERICNANOPARTICLES AS VEHICLES FOR ... this date, polymericdrugdelivery systems based on hydrogels, nanoparticles, microspheres, and lipid-based drugdelivery systems (e.g liposomes and microemulsions) have been developed for oral ... cancer treatment have been demonstrated as early as 1974 for liposomes [6], and 1980 forpolymericnanoparticles [7] Till this date, several drugdelivery systems have moved into clinical application...
... The polymerase chain reaction (PCR) was carried out for 30 cycles (98°C for 15 sec, 58°C for 30 sec, and 72°C for 40 sec and finally 72°C for min) The integrity of the cDNA was assayed by RTPCR ... Luc-H19 (control group) were performed at days 10, 12, 14 and 16 after cell inoculation Tumor dimensions were measured, and the tumor volume was calculated according to the formula (width)2 × length ... subcutaneous tumors In order to develop a model for heterotopic ovarian tumors, ES-2 ovarian carcinoma cells were subcutaneously injected into the dorsa of 6–7 week old CD-1 female mice Tumors were...
... Samples of the tumors were fixed in 4% buffered formaldehyde and processed for histological examination for evidence of necrosis and persistent tumor Computerized measurements of tumor surface ... Samples of the tumors were fixed in 4% buffered formaldehyde and processed for histological examination for evidence of necrosis and persistent tumor Computerized measurements of tumor surface ... ISH was performed on successive slides of TCC tissue for H19 and IGF2-P4 transcripts The intensity of hybridization signal was indicated as (0) for no staining, (+1) for weak, (+2) for moderate...
... applications fordrug and DNA delivery Mini Rev Med Chem 2009, 9:463-469 59 Kircheis R, Schuller S, Brunner S, Ogris M, Heider KH, Zauner W, Wagner E: Polycation-based DNA complexes for tumor- targeted ... nucleus for reporter gene expression advanced class of drugdelivery systems, with several formulations in clinical trials Over the past 20 years, a variety of techniques have been developed for ... intracellularly [11] Biodegradable PLGA nanoparticles (NPs) have been investigated for sustained and targeted/ localized delivery of different agents, including drugs, proteins and peptides and recently,...
... in tumors [121] HA-conjugated drugs CD44 can internalize HA [122] Thus, HA-carrying drugs alone or encapsulated drugs in liposomes have the potential to be used as targeted drugs, as well as drug ... PLGA nanoparticlesfordelivery of 5-fluorouracil Drug Deliv 17, 561–572 Yadav AK, Mishra P & Agrawal GP (2008) An insight on hyaluronic acid in drug targeting and drugdelivery J Drug Target 16, ... complexes for systemic tumor- targeted gene transfer Bioconjug Chem 14, 222–231 Bellocq NC, Pun SH, Jensen GS & Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor- targeted...
... vivo is not only dependent on the targetedtumor antigen but also on the tumor characteristics, e.g., tumor type (hematological malignancies or solid tumors); tumor mass; accessibility and density ... residues to be retained is generally unique for each reshaped antibody and can therefore be difficult to foresee Such approach was successfully used for humanizing a MAb 4D5 against the product ... intermolecular VH-VL pairings with formation of a 60 kDa noncovalent scFv dimer “diabody” (104) Prolonged tumor retention in vivo and higher tumor to blood ratios reported for diabodies over scFv monomers...
... necessary for improved therapeutic efficacy of antibody -targeted liposomal drugs Cancer Res 62, 7190–7194 (2002) 20 Allen, T. M Long-circulating (sterically stabilized) liposomes fortargeted drug- delivery ... multidrug resistance The delivery of drugs through targeted nanocarriers that are internalized by cells provides an alternative route to diffusion of drugs into cells This approach may allow targeted ... therapeutics95, polymeric nanoparticles9 6, lipid nanocapsules97 and micelles98 within cell lines or in mouse tumour models Combination treatments with targeted nanocarriers for selective delivery of drugs...
... localized tumor perfusion is not a reasonable option for many tumor types, especially for widely metastatic disease To overcome the problem, researchers are now developing targeted TNF-α delivery ... targeting of the TNF-α protein to the tumor and delivery by gene therapy We recently reported the evaluation of a potential novel gene therapy for melanoma using a targeted adeno-associated virus-phage ... in anti -tumor therapy BMC Cell Biol 2009, 10:63 Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK: Tumor vasculature -targeted delivery...
... shown CB when they either had objective response in the form of complete response (CR) or partial response (PR); or had stable disease (SD) for ≥ months in accordance with UICC criteria [9,10] • ... treatment Patient and tumor characteristics are shown in Table Two patients were still on follow-up at analysis The results from “withdrawal” from different agents are shown in the Table Drugs prior to ... in-vivo study [12], athymic mice were transplanted with ER positive tumor cells and then exposed to tamoxifen or placebo The tumors regressed initially over months but started to grow towards...
... http://www.wjso.com/content/7/1/44 • Formation of a collaborative task force group that aims at more availability and affordability of systemic cancer therapy in LMCs For novel drugs e) Conducted with appropriate ... new markets -Old drugs can bring new profits and its use may pave ways for novel drugs 10 The outcome of the communications and meeting for the year 2009 would be a road map for the win-win initiative ... the required infrastructure for the clinical research and trials with pragmatic goals that would be ideally suited to LMCs, few suggestions for this are: For older drugs a) To tailor treatment...
... Relationship between lymph nodal metastasis and tumor characteristics (T classification, lymphatic vessel invasion, tumor location, tumor size and tumor differentiation) was also evaluated The ... accounted for the major challenge for radiation oncologists in the treatment of this disease However, no evidence-based recommendations for target volume definition especially CTV have been provided for ... based on tumor locations The metastatic rates of subgroups of lymph nodes for Page of 13 patients with pancreatic head cancer were listed in Table (not including paraaortic lymph nodes) For patients...
... dose for not macroscopically involved nodes) the upper jaws of the upper volume are closed asymmetrically for a length of cm After 55,8 Gy (dose for macroscopically involved nodes) the primary tumor ... volume, because the primary tumor is partially directly adherent to the esophagus, for about cm it receives the full tumor dose at a major part of its circumference Peripheral tumor, hilus/mediastinum ... for the heart is 3,5 Gy Peripheral tumor located lateral, but close to hilus/ mediastinum (Figure 5) Junction plane above the primary tumor The isocenter is set in the center of the primary tumor, ...